ROCKWELL MEDICAL INC
RMTINASDAQTrading Snapshot
- Day Range
- $8.65 β $8.82
- 52-Week Range
- $4.89 β $12.90
- Volume
- $6.77B
- Avg Volume
- $5.45B
- Shares Outstanding
- 3.9M
- Next Earnings
- Dec 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $69M
- Last Q Revenue
- $18M
- P/E Ratio
- -6.2
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-1.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.9%
Why Investors Own RMTI
- βHigh-growth profile β revenue up +12.4% YoY with expanding US Equity exposure.
- βHealthy economics β 75% gross margin and 10% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ROCKWELL MEDICAL INC
RMTIAbout ROCKWELL MEDICAL INC
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript

Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates
Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.

Rockwell Medical Announces Second Quarter 2026 Results
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodial

Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rockwell Medical Advances Quality and Regulatory Leadership
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Company.

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical received notice from Nasdaq that it regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).